UK Biobank
↗Stockport, United Kingdom
UK Biobank is a large-scale biomedical database and research resource that contains in-depth genetic and health information from half a million UK participants. It is a major global resource for researchers, providing access to de-identified data including whole genome sequencing, proteomics, and extensive imaging. The organization operates as a registered charity and a company limited by guarantee, supported by the UK government and major medical charities.
Unlike traditional pharmaceutical companies, UK Biobank does not develop drugs internally; rather, it provides the critical data infrastructure and biological samples that enable pharmaceutical companies and academic institutions to discover new treatments for life-threatening diseases such as cancer, heart disease, stroke, and dementia. The resource is widely considered the gold standard in population-based health research.
CLASSIFICATION
Company Type:Diagnostics
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Biomedical Research & Data Services
SIZE & FINANCIALS
Employees:201-500
Revenue:$50M-$100M
Founded:2003
Ownership:nonprofit
Status:operating
FUNDING
Stage:Non-Profit/Grant-Funded
Total Raised:$300M+
Investors:Wellcome Trust, Medical Research Council (MRC), UK Research and Innovation (UKRI), National Institute for Health and Care Research (NIHR), Cancer Research UK, British Heart Foundation, Schmidt Futures, Griffin Catalyst, Amazon Web Services (AWS)
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Data/Research Resource)
Modalities:Genomics, Proteomics, Biomarkers, Imaging
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:UK Biocentre Limited
Key Partnerships:Regeneron Genetics Center (Genomic sequencing lead), DNAnexus (Research Analysis Platform provider), Oxford Nanopore (Epigenetic dataset development), Pharma Consortium (14 major biopharma partners including GSK, AstraZeneca, and J&J)
COMPETITION
Position:Leader
Competitors:FinnGen, All of Us Research Program, 23andMe (Personal Genome Service), deCODE genetics (Amgen)
LEADERSHIP
Key Executives:
Professor Sir Rory Collins - CEO and Principal Investigator
Dr. Mark Effingham - Deputy CEO
Professor Naomi Allen - Chief Scientist
Scientific Founders:Sir Rory Collins
Board Members:Professor Lord Ajay Kakkar (Chair), Professor Sir Michael Ferguson, Dr. Nicola Perrin, Dame Nancy Rothwell
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with UK Biobank. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.